copanlisib
Showing 51 - 59 of 59
Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Positive Trial (Copanlisib, Fulvestrant, Laboratory
Withdrawn
- Estrogen Receptor Positive
- +3 more
- Copanlisib
- +3 more
- (no location specified)
Aug 13, 2018
Advanced Malignant Solid Tumor, Bladder Carcinoma, Breast Carcinoma Trial in Guam, Puerto Rico, United States (drug, procedure,
Recruiting
- Advanced Malignant Solid Neoplasm
- +49 more
- Adavosertib
- +36 more
-
Birmingham, Alabama
- +1429 more
Aug 17, 2022
Lymphoma, Mantle-Cell Trial in United States (Copanlisib (BAY80-6946))
Terminated
- Lymphoma, Mantle-Cell
- Copanlisib (BAY80-6946)
-
Baltimore, Maryland
- +4 more
Sep 29, 2017
Non Hodgkin Lymphoma Trial in Belgium, France, United Kingdom (Copanlisib (BAY80-6946))
Completed
- Non Hodgkin Lymphoma
- Copanlisib (BAY80-6946)
-
Bruxelles - Brussel, Belgium
- +8 more
Jun 15, 2017
Tumors Trial in Scottsdale, Pittsburgh, San Antonio (Copanlisib (Aliqopa, BAY80-6946))
Completed
- Neoplasms
- Copanlisib (Aliqopa, BAY80-6946)
-
Scottsdale, Arizona
- +2 more
Oct 5, 2017
Tumors Trial in Germany, Netherlands, United States (Copanlisib + Refametinib (BAY86-9766))
Completed
- Neoplasms
- Copanlisib + Refametinib (BAY86-9766)
-
Scottsdale, Arizona
- +7 more
Apr 16, 2015
Healthy Volunteers Trial in Zuidlaren (Copanlisib (BAY80-6946))
Completed
- Healthy Volunteers
- Copanlisib (BAY80-6946)
-
Zuidlaren, Netherlands(unnamed)
Oct 27, 2014